



OPEN ACCESS

ORIGINAL ARTICLE

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner

Palak J Trivedi,^{1,2} Joseph Tickle,¹ Mette N rdal Vesterhus,^{3,4} Peter J Eddowes,¹ Tony Bruns,^{5,6} Jani Vainio,⁷ Richard Parker,^{1,2} David Smith,⁷ Evaggelia Liaskou,¹ Liv Wenche Thorbj rnsen,^{3,4} Gideon M Hirschfield,^{1,2} Kaisa Auvinen,^{8,9} Stefan G Hubscher,¹⁰ Marko Salmi,^{8,9} David H Adams,^{1,2} Chris J Weston¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2016-312354>).

For numbered affiliations see end of article.

Correspondence to

Dr Chris J Weston, National Institute of Health Research (NIHR) Birmingham Liver Biomedical Research Centre Institute of Immunology and Immunotherapy, University of Birmingham, Wolfson Drive, Birmingham B152TT, UK; c.j.weston@bham.ac.uk

Received 31 May 2016
Accepted 23 March 2017
Published Online First
20 April 2017

ABSTRACT

Objective Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of IBD. This clinical association is linked pathologically to the recruitment of mucosal T cells to the liver, via vascular adhesion protein (VAP)-1-dependent enzyme activity. Our aim was to examine the expression, function and enzymatic activation of the ectoenzyme VAP-1 in patients with PSC.

Design We examined VAP-1 expression in patients with PSC, correlated levels with clinical characteristics and determined the functional consequences of enzyme activation by specific enzyme substrates on hepatic endothelium.

Results The intrahepatic enzyme activity of VAP-1 was elevated in PSC versus immune-mediated disease controls and non-diseased liver ($p < 0.001$). The adhesion of gut-tropic $\alpha 4\beta 7^+$ lymphocytes to hepatic endothelial cells in vitro under flow was attenuated by 50% following administration of the VAP-1 inhibitor semicarbazide ($p < 0.01$). Of a number of natural VAP-1 substrates tested, cysteamine—which can be secreted by inflamed colonic epithelium and gut bacteria—was the most efficient (yielded the highest enzymatic rate) and efficacious in its ability to induce expression of functional mucosal addressin cell adhesion molecule-1 on hepatic endothelium. In a prospectively evaluated patient cohort with PSC, elevated serum soluble (s)VAP-1 levels predicted poorer transplant-free survival for patients, independently (HR: 3.85, $p = 0.003$) and additively (HR: 2.02, $p = 0.012$) of the presence of liver cirrhosis.

Conclusions VAP-1 expression is increased in PSC, facilitates adhesion of gut-tropic lymphocytes to liver endothelium in a substrate-dependent manner, and elevated levels of its circulating form predict clinical outcome in patients.

Significance of this study

What is already known on this subject?

- Primary sclerosing cholangitis (PSC) is an immune-mediated hepatobiliary disease strongly associated with IBD, usually colitis.
- Under normal circumstances, expression of mucosal addressin cell adhesion molecule (MAdCAM)-1 is restricted to the gut, but in PSC it can also be found on hepatic endothelial cells, where it is responsible for the recruitment of mucosal effector $\alpha 4\beta 7$ positive T-cells to the liver.
- We have recently shown that the aberrant expression of MAdCAM-1 in PSC liver may involve a combination of inflammation and activation of the enzyme vascular adhesion protein (VAP)-1, a potent amine oxidase.

What are the new findings?

- Hepatic VAP-1 enzyme activity is increased in PSC compared with non-inflamed liver, and expressed at a similar level to resected colon from patients with colitis.
- VAP-1 can catabolise a diverse range of substrates, with the most potent inducer of enzyme activity being cysteamine—an amine that can be released by the colonic epithelium and enteric pathogens.
- The degree to which VAP-1 enzyme activity facilitates the adhesion of $\alpha 4\beta 7$ T-cells to hepatic endothelium is substrate-dependent.
- Circulating soluble VAP-1 levels (sVAP-1) are heightened in patients with PSC, correlate with disease severity and can be used to prospectively stratify clinical outcome.

INTRODUCTION

Primary sclerosing cholangitis (PSC) is a progressive fibroinflammatory cholangiopathy strongly associated with colonic IBD.^{1–3} This clinical phenotype has generated several hypotheses linking

inflammation in the gut and liver, one of which centres on aberrant lymphocyte homing.^{4, 5} Ordinarily, the gut and liver harbour distinct endothelial phenotypes, which provide a mechanism to compartmentalise tissue-specific lymphocyte



To cite: Trivedi PJ, Tickle J, Vesterhus MN, *et al.* *Gut* 2018;**67**:1135–1145.

Significance of this study

How might it impact on clinical practice in the foreseeable future?

- ▶ The ability of VAP-1 to catabolise amine substrates, potentially secreted by gut epithelium or enteric pathogens, provides a theoretical link between altered colonic microbiota and mucosal immunity in PSC disease pathogenesis.
- ▶ sVAP-1 represents a biologically linked, mechanistically driven serum marker of clinical outcome in patients with PSC.
- ▶ Modulating the recruitment of mucosal lymphocytes to the liver by targeting VAP-1 highlights an avenue for therapeutic exploration.

recruitment.⁶ In the gut, expression of mucosal addressin cell adhesion molecule (MAdCAM)-1 on mucosal endothelium is responsible for recruiting intestinal lymphocytes that are imprinted with tissue-specific tropism; specifically those which express the MAdCAM-1 receptor, $\alpha 4\beta 7$.⁷ Under normal circumstances, expression of MAdCAM-1 is restricted to the gut, but in PSC can also be detected on hepatic endothelium where it promotes recruitment of mucosal $\alpha 4\beta 7^+$ T cells to the liver.⁸ The latter population are predominantly effector memory lymphocytes,^{8, 9} which upon reactivation result in a T cell rich portal infiltrate within the liver, and an iterative inflammatory response therein.

The factors leading to aberrant expression of MAdCAM-1 in PSC liver are not known, but may involve inflammation and activation of vascular adhesion protein (VAP)-1,^{10, 11} an adhesion molecule that is also endowed with potent amine oxidase activity. In humans, VAP-1 is constitutively expressed on the hepatic endothelial surface,^{12, 13} and through its catalytic function, VAP-1-mediated oxidation of methylamine can induce MAdCAM-1 expression by endothelial cells.¹⁰ However, VAP-1 is potentially capable of catabolising a diverse range of substrates beyond methylamine; and it is plausible that in the presence of enteric dysbiosis and/or an inflamed 'leaky' gut,¹⁴ increased portal vein amine levels lead to intrahepatic enzyme activation, upregulated hepatic endothelial MAdCAM-1 expression and recruitment of mucosal effector T cells to the liver.^{4, 5}

The aims of this study were to compare VAP-1 expression in PSC to that observed in non-diseased liver, correlate serum levels with patient characteristics and clinical outcome, and determine the functional consequences of enzyme activation through a divergent amine substrate panel.

MATERIALS AND METHODS**Human tissue samples**

Liver tissue was acquired during transplantation from patients with chronic end-stage disease, and from healthy donor livers surplus to requirements. Colonic tissue was procured via surgical resections in colitis refractory to medical treatment (UC), and distal-to-tumour segments in non-colitis associated colonic cancer (NC). All samples were obtained with Local Research and Ethics Committee approval and informed patient consent (Local Research and Ethics Committee Birmingham references: 2003/242, renewed 2012; and 06/Q2702/61).

Demonstration and quantification of VAP-1 in human tissue

Prior to determining VAP-1 expression in human liver, representative tissue sections were stained with Oil Red O (Sigma), which stains neutral triglycerides and lipids. Steatosis was quantified by the proportion of section area that stained positive for dye as assessed by ImageJ analysis.^{15, 16} Sections were only used for study when 2% or less of the surface area stained positive, indicating minimal or no excess steatosis.

Immunohistochemistry

Chromogenic staining was used to visualise VAP-1 in frozen liver tissue and confocal microscopy to confirm cellular localisation^{12, 17} (see online supplementary table S1). All immunohistochemical sections were assessed by a specialist hepatopathologist.

Absolute quantification of VAP-1 mRNA

Quantification of VAP-1 mRNA expression in human liver was assessed by qRT-PCR (see online supplementary table S2). Given the absence of a single, known housekeeping gene exhibiting stability across all aetiologies and between varying stages of human liver injury,^{18, 19} mRNA expression was determined by absolute quantification of samples. Briefly, copy number of VAP-1 in matched amounts of starting total RNA from each sample was measured via a calibration curve of known dilutions of a linearised plasmid encoding the VAP-1 gene ranging from 10 copies/ μ L to 10⁵ copies/ μ L, as previously described.¹² All starting mRNA concentrations were standardised and qRT-PCR reactions performed using 100 ng starting material run in triplicate wells.

VAP-1 enzyme assays

VAP-1 enzyme activity was determined in protein lysates from liver and colon using Amplex-UltraRed Reagent as a stoichiometric fluorogenic substrate for horseradish peroxidase and by quantifying the rate of H₂O₂ production during a deamination/oxidation reaction (see online supplementary table S3).¹³ To ensure all measured output was specific to VAP-1, test wells were always run in parallel to identical samples containing the urea derivative semicarbazide (250 μ M; Sigma), which is a complete inhibitor of VAP-1 activity.¹³ The value from semicarbazide-treated samples was then subtracted from the enzymatic rate in inhibitor-free wells.

Evaluating substrate-dependent variations in enzyme kinetics

Putative, naturally occurring substrates of human VAP-1 were selected based on inclusion in the human metabolome database V2.5 (<http://www.hmdb.ca>), and with reference to Shen *et al*,²⁰ specifically cysteamine, methylamine, dopamine, ethylamine and phenethylamine (Sigma). A 96-well plate was loaded with 50 ng recombinant VAP-1 (Biolegend) in 100 μ L Dulbecco's phosphate-buffered saline with increasing concentrations of test substrate supplemented to test wells. A H₂O₂ standard curve was created, and enzyme activity quantified using the Amplex-UltraRed detection system across increasing concentrations of test substrate for a fixed concentration of VAP-1 under atmospheric conditions. Kinetic parameters were estimated by Michaelis-Menten methodology (see online supplementary figure 1). Benzylamine served as an internal positive control.

Determining the consequences of VAP-1 activation

Hepatic endothelial cells (HEC) were extracted from whole liver and grown till confluence as previously described.^{10, 21}

Cell-based ELISAs

An ELISA of cultured HEC (passage 3–4) was used to investigate the expression of MAdCAM-1, following cell stimulation with tumour necrosis factor (TNF) α (20 ng/mL; Peprotech, UK) in the absence or presence of amine substrates at concentrations yielding the maximum apparent enzymatic rate (V_{\max}^{APP}) (see online supplementary file 1).

Flow-based adhesion assays

Flow-based adhesion assays were conducted to assess the functional consequences of amine exposure and VAP-1 inhibition on HEC-mediated lymphocyte recruitment, as described previously.^{10, 21} Briefly, confluent monolayers of HEC were cultured in microcapillary flow chamber microslides (Ibidi, Germany), and stimulated with TNF α (20 ng/mL) \pm amine substrate supplemented HEC media, in the absence or presence of semicarbazide (250 μ M) (see online supplementary file 2).

To obtain purified CD3⁺ α 4 β 7⁺ T cells, peripheral blood lymphocytes were subject to fluorescence-activated cell sorting (MoFlo XDP High-Speed Cell Sorter in purity mode; Beckman Coulter) (see online supplementary table S4). Isolated cells were incubated overnight (Roswell Park Memorial Institute medium +10% foetal calf serum in a 48-well culture plate; Corning Costar) to facilitate recycling of surface receptors. The following day, cells were washed, pelleted and viability confirmed by Trypan blue exclusion, before being resuspended (10⁶ cells/mL) in serum-free basal endothelial media containing 0.1% bovine serum albumin, ready for perfusion.

Quantification of circulating soluble VAP-1 in clinical samples

Soluble (s)VAP-1 values were quantified in human circulation using a europium-coupled, time-resolved immunofluorometric assay (see online supplementary table S5), and results validated through a chemiluminescence detection technique as per Aalto *et al*²² (see online supplementary file 3). Serum samples were obtained from patients with PSC, primary biliary cholangitis/PBC, autoimmune hepatitis/AIH, UC alone/UC and healthy volunteers without evidence of liver disease or IBD. Notably, as liver biopsy no longer forms routine standard of care in PSC or PBC,²³ in the absence of histological data, the presence of cirrhosis was identified according to a combination of clinical features (ascites/varices/hepatic encephalopathy), laboratory indices (hypoalbuminaemia/thrombocytopenia/prolonged international normalised ratio) and radiology (coarse or irregular liver \pm reversed portal flow/splenomegaly/ascites).

Statistical analysis

Non-parametric data are presented using median and IQRs unless otherwise specified. The Mann-Whitney test was conducted when comparing continuous data between two independent groups, and Kruskal-Wallis test ($p < 0.001$) with Bonferroni-Dunn post hoc correction for multiple groups. Non-parametric measures of statistical dependence between continuous variables were conducted using Spearman's rank correlation coefficient.

In prospective clinical outcome studies, time-zero was set as the point of blood sampling, and the primary endpoint defined as transplant-free survival; patients without a clinical event were censored at date of last clinic follow-up. The impact of continuous variables on clinical endpoints was evaluated by receiver operator characteristic curve analysis, and an optimal cutpoint selected (Youden Index) from a derivation cohort (Birmingham, UK) before being tested in a validation series of patients (Oslo, Norway). Cox proportional hazards models were fit to assess

the impact of individual covariates on the instantaneous rate of events, with time-to-event analysis ascertained through Kaplan-Meier estimates (SPSS V.21; IBM, USA).

RESULTS

VAP-1 expression is altered in PSC liver

In non-diseased liver, VAP-1 expression as shown by immunohistochemistry was largely confined to the walls of blood vessels and the hepatic sinusoids, with the latter being most evident in centrilobular regions (see online supplementary figure 2A–C). VAP-1 expression was increased in immune-mediated liver disease, including PSC, wherein sinusoidal staining was present throughout cirrhotic nodules (see online supplementary figure 2D) (see online supplementary figure 3).

We have previously shown that VAP-1 is expressed by HEC, in addition to α smooth muscle actin (α SMA) hepatic stellate cells and activated myofibroblasts in cirrhosis.¹² To this effect, strong VAP-1 expression was seen in the fibrous septa and the walls of portal/septal vessels in PSC liver (see online supplementary figure 2E–F). Confocal immunofluorescence confirmed VAP-1 colocalisation with α SMA in the walls of portal/septal vessels and stromal cells within fibrous septa (see online supplementary figure 4). VAP-1 staining in portal/septal vessels was present in close proximity to CD31⁺ endothelial cells lining these vessels (see online supplementary figure 5), as previously described.¹² Conversely, VAP-1 did not colocalise with EpCAM⁺ bile ducts or proliferating bile ductules in PSC liver (see online supplementary figure 6).

To quantify the level of hepatic VAP-1 expression, gene transcription was measured using qRT-PCR on cDNA derived from human liver tissue. Levels of VAP-1 mRNA were significantly greater in diseased versus non-diseased liver explants, with the highest levels seen in PSC ($p = 0.003$) (see online supplementary figure 7).

VAP-1 enzyme activity is increased in PSC liver

Consistent with immunohistochemical staining patterns and qRT-PCR, we found that VAP-1 enzyme activity was elevated in PSC versus normal liver ($p < 0.001$) (figure 1A). Given the clinical association with IBD, VAP-1 enzyme activity was also assessed in resected colonic tissue. Levels in UC were similar to those of PSC liver and greater than that in non-inflamed human colon (figure 1B).

VAP-1 enzyme activity supports the adhesion of α 4 β 7⁺ lymphocytes to HEC

It has previously been demonstrated that VAP-1 enzyme activity enhances MAdCAM-1-dependent binding of an α 4 β 7-expressing β -lymphoblastoid cell line to HEC.¹⁰ We now show that highly purified α 4 β 7⁺ T cells isolated from peripheral blood (see online supplementary figure 8) also undergo adhesion to hepatic endothelium on which VAP-1 enzyme activity is activated by the model substrate methylamine (figure 2). This process was inhibited by approximately 50% with the selective VAP-1 enzyme inhibitor semicarbazide, although no significant differences in the proportion of cells undergoing transmigration were seen. These findings are consistent with the role of MAdCAM-1/ α 4 β 7 in the lymphocyte recruitment cascade where they support adherence but not transmigration.¹⁰

VAP-1 enzymatic activity is substrate-dependent

To profile the enzymatic rate following provision of other naturally occurring substrates, the amine oxidase activity of a fixed amount of purified VAP-1 was quantified across increasing substrate concentrations until the apparent maximum saturating




Figure 1 Vascular adhesion protein-1 (VAP-1) enzyme activity in human liver and colon. (A) VAP-1 enzyme activity in tissue lysates from explanted primary sclerosing cholangitis (PSC) liver (n=9) is compared with autoimmune hepatitis (AIH; n=12), primary biliary cholangitis (PBC; n=15) and non-diseased resected liver (NL; n=10); and (B) resected tissue from distal-to-tumour segments of non-colitis associated cancer (NC; n=7) and UC (n=8). Mean enzyme activity of three repeats per patient is presented.

enzyme activity was reached ($V_{\text{app}}^{\text{max}}$), and the resulting kinetic rates measured (figure 3A). Following a series of dose-finding studies and by approximating Michaelis-Menten constants, we were able to develop a hierarchy of substrates based on enzymatic efficiency ($k_{\text{cat}}^{\text{app}}/K_M^{\text{app}}$) with the highest rate seen for cysteamine (see online supplementary table S6). This was of particular interest given that cysteamine can be generated by the colonic epithelium and induce colitis,^{24–30} and also by bacteria associated with enteric dysbiosis in PSC-IBD.¹⁴

A cell-based ELISA was then used to measure the impact on MAdCAM-1 induction in response to varying substrate provision (figure 3B). Again, cysteamine was shown to be the most potent of all amines tested, resulting in significantly higher MAdCAM-1 expression by HEC than methylamine and dopamine (another potent VAP-1 substrate). All experiments were carried out in the presence of TNF α to mimic local inflammation.^{21 31–34} Moreover, cysteamine-stimulated HEC supported adhesion of $\alpha 4\beta 7^+$ T cells under flow to a significantly greater degree than that observed with methylamine at matched concentrations (figure 3C), suggesting that as a substrate, cysteamine is also associated with greatest VAP-1 efficacy.

Circulating soluble VAP-1 levels are elevated in the sera of patients with PSC

In addition to its expression within the liver, VAP-1 can be released into the circulation in soluble form (sVAP-1).³⁵ The hepatic vasculature is an important source of sVAP-1, and we have recently shown that it is also released by activated hepatic stellate cells and liver myofibroblasts—key cellular mediators of tissue fibrosis.¹² We measured serum sVAP-1 in a cohort of patients under active follow-up using an immunofluorescence ELISA (table 1), and found higher values in those with PSC (n=134; 532 ng/mL, IQR 432–668 ng/mL) compared with AIH (n=97; 433 ng/mL, IQR 355–548 ng/mL), PBC (n=48; 470 ng/mL, IQR 374–653 ng/mL), healthy control subjects (n=54; 425 ng/mL, IQR 336–466 ng/mL) and patients with colitis alone (n=50; 413 ng/mL, IQR 348–489 ng/mL) (figure 4A,B).

A greater number of patients with PSC displayed features of established cirrhosis, together with an increased number of clinical events over time compared with our PBC and AIH groups. In light of this observation, we then stratified our autoimmune liver disease cohort according to elevated sVAP-1 values, via dichotomisation at the median for the overall cohort (cut-off:




Figure 2 Vascular adhesion protein-1 (VAP-1) supports adhesion of $\alpha 4\beta 7^+$ lymphocytes to hepatic endothelial cells (HEC). Circulating $\alpha 4\beta 7^+$ T cells were enriched from blood donors to over 90% purity, perfused over a HEC monolayer under flow (0.05 Pa) and the number of adherent cells recorded. (A) HEC were stimulated with tumour necrosis factor (TNF) α (20 ng/mL), methylamine (MA, 100 μ M) or both for 4 hours. (B) The impact of VAP-1 enzyme inhibition was tested using semicarbazide (ScZ). Data represent the mean of n=3 (\pm SD).




Figure 3 Kinetic profiling of vascular adhesion protein (VAP-1) amine substrates. (A) Non-linear fit curves showing vascular adhesion protein (VAP-1) activity across a range of concentrations of potential substrates. Enzymatic rates are measured by Amplex-UltraRed. Each point represents mean of three replicates. (B) Mucosal addressin cell adhesion molecule (MAdCAM)-1 expression by hepatic endothelial cells (HEC) following stimulation for 4 hours with tumour necrosis factor (TNF) α alone, or plus substrates methylamine (MA), dopamine (DA) or cysteamine (CA) at concentrations yielding V_{max}^{app} (n=3). (C) Flow-based adhesion assays of $\alpha 4\beta 7^+$ cells perfused across HEC treated for 4 hours with TNF α alone or in combination with MA or CA at 50–100 μ M. Mean \pm SD of three experiments shown.

485 ng/mL). To this effect, PSC retained a significant association with heightened sVAP-1 independently of the presence of liver cirrhosis (adjusted OR 1.86, 95% CI 1.10 to 3.14; $p=0.021$).

sVAP-1 is associated with disease severity and predictive of clinical outcome

When patients with PSC were studied in more detail, elevated values were seen particularly in those with cirrhosis compared with non-cirrhotic individuals, but with no statistically significant differences between compensated versus decompensated disease (figure 4C,D) (table 2).

Having identified an association with indices of advanced disease, the ability of sVAP-1 to predict clinically significant endpoints was evaluated prospectively. In the Birmingham derivation cohort, 51 patients underwent liver transplantation or sustained a liver-related death (n=44 and n=7, respectively), yielding an incidence rate of 19.7 clinical events per 100 patient-years. Survival analysis was restricted to those patients not listed for liver transplantation at time of sampling and with a minimum 3-month follow-up (n=104; median event-free survival from time of serum sampling: 39.0 months, IQR 32.1–45.9 months, figure 5A), in which the prognostic value of

sVAP-1 was evident on a continuous scale (see online supplementary figure 9A). An optimal cutpoint of 529 ng/mL was determined via the Youden Index method and shown to stratify clinical outcome (HR: 3.76, 1.68–8.47, $p=0.001$) (figure 5B) independent of other risk predictors on multivariable analysis (adjusted HR: 3.85, 1.68–8.47, $p=0.003$) (table 3).

Given that liver cirrhosis and sVAP-1 levels exhibited a significant statistical interaction ($p < 0.01$), the additive predictive value of the latter was then assessed exclusively in a subset of patients with PSC who already had advanced liver disease. Despite this restriction, elevated sVAP-1 levels were still able to stratify the subgroup of cirrhotic patients with PSC at highest risk of liver transplantation/death (HR: 2.02, 1.17–3.51, $p=0.012$) (figure 5C). Reciprocally, elevated sVAP-1 values discriminated the risk of poorer clinical outcome in patient groups having a normal serum bilirubin, a normal serum albumin and/or a normal platelet count (see online supplementary figure 10).

Validation of sVAP-1 as a biomarker for patients with PSC

To substantiate the findings of clinical outcome studies, we quantified sVAP-1 levels using a second, independent detection system (chemiluminescence), and showed strong correlation

Table 1 Demographic variation across sample populations

| | PSC (n=134 overall)* | PBC (n=48) | AIH (n=97) | IBD (n=50) | HC (n=54) |
|------------------------------------|---|---|---|------------|------------|
| Patient age† | 42 (29–59) yrs. | 55 (49–63) | 49 (29–61) | 35 (26–54) | 34 (38–37) |
| Male gender | 83 (62) | 3 (6) | 21 (21) | 31 (62) | 43 (80) |
| UDCA exposure within past 3 months | 96 (72) | 34 (71) | 1 (1) | | |
| Laboratory parameters‡ | | | | | |
| Serum AST | 66 (34–100) IU/L | 40 (26–80) IU/L | 31 (23–48) IU/L | | |
| Serum ALT | 61 (34–105) IU/L | 35 (25–77) IU/L | 26 (20–52) IU/L | | |
| Serum ALP (ratio to ULN)‡ | 2.50 (1.80–4.11) | 2.39 (1.43–3.34) | 1.25 (1.11–1.81) | | |
| Bilirubin | 20 (11–48) $\mu\text{mol/L}$ | 13 (7–24) $\mu\text{mol/L}$ | 10 (7–14) $\mu\text{mol/L}$ | | |
| Albumin | 43 (38–45) g/dL | 42 (40–45) g/dL | 44 (41–47) g/dL | | |
| Platelet count | 200 (128–298) $\times 10^3$ cells/mm ³ | 247 (153–310) $\times 10^3$ cells/mm ³ | 221 (139–283) $\times 10^3$ cells/mm ³ | | |
| INR | 1.1 (1.0–1.2) | 1.0 (0.9–1.1) | 1.0 (1.0–1.1) | | |
| Sodium | 141 (139–142) mmol/L | 141 (140–143) mmol/L | 142 (140–144) mmol/L | | |
| Creatinine | 72 (58–82) $\mu\text{mol/L}$ | 64 (58–71) $\mu\text{mol/L}$ | 66 (60–75) $\mu\text{mol/L}$ | | |
| IgG | 14.17 (11.77–17.71) g/L | 14.59 (11.18–17.74) g/L | 14.16 (10.68–16.97) g/L | | |
| ANA-positive | 60 (45) | 21 (49) | 68 (70) | | |
| ASMA-positive | 41 (31) | 11 (26) | 64 (66) | | |
| Cirrhosis† | 95 (71) | 24 (50) | 45 (46) | | |
| Decompensated | 28 | 6 | 4 | | |
| MELD score† | 6 (6–10) | 6 (6–7) | 6 (6–6) | | |
| Child-Turcotte-Pugh score† | | | | | |
| A | 78 (58) | 35 (73) | 86 (87) | | |
| B | 52 (39) | 10 (21) | 9 (9) | | |
| C | 4 (3) | 1 (2) | 2 (2) | | |
| Clinical events | | | | | |
| Liver transplantation | 44 | 11 | 0 | | |
| Death | 12 | 5 | 4 | | |

Data for categorical variables expressed as number with percentages in parenthesis. Continuous variables expressed as median (IQR).

*Three patients with small-duct PSC.

†At time of sampling.

‡Ratio to upper limit of normal provided, given variation between assay methods over time.

AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine transaminase; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; AST, aspartate transaminase; HC, healthy controls; IgG, immunoglobulin G; INR, international normalised ratio; MELD, model for end-stage liver disease score; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.

between both techniques (see online supplementary figure 11). Moreover, when applying the chemiluminescence assay, serum sVAP-1 values retained predictive value of transplant-free survival in our derivation cohort (see online supplementary figure 9B), with an optimum cutpoint of 923 ng/mL. Patients with a chemiluminescence-derived sVAP-1 concentration above this value carried a significantly increased risk of future clinical events (HR: 5.10, 1.95–13.34, $p=0.001$).

Next, we obtained serum samples from an external PSC cohort from Oslo (Norway), in an attempt to validate the biomarker potential of sVAP-1. Patient characteristics and comparison against the Birmingham derivation cohort are provided in online supplementary table S7. As such, elevated serum sVAP-1 in the validation cohort also associated with significantly poorer transplant-free survival (see online supplementary figure 12), characterising a group at high risk of disease progression (HR: 3.06, 1.39–6.78, $p=0.006$).

DISCUSSION

The results of our study indicate that in PSC, expression and enzyme activity of VAP-1 are increased in the liver, which is reflected by increased circulating soluble levels. These findings have important implications for understanding disease pathogenesis, because we subsequently show how activation of VAP-1 on hepatic endothelium increases the ability to recruit $\alpha 4\beta 7^+$ T cells from blood that were originally activated in the gut. Because pathophysiological substrates for VAP-1 are not known,

we also studied a range of natural amines in their ability to induce enzyme activation. In so doing, we found that the most potent substrate is cysteamine which has been shown to induce colitis and colonic cancer in mice;^{27–30} an intestinal phenotype mirrored clinically in patients with PSC.^{1–3} Furthermore, cysteamine when administered to hepatic endothelium resulted in increased MAdCAM-1 expression and an enhanced ability to recruit $\alpha 4\beta 7^+$ cells under flow. This lymphocytic phenotype defines a mucosa-activated, effector memory cell population, which are known to be recruited to PSC liver consequent to aberrant endothelial expression of MAdCAM-1.⁸

Whether amine substrates are generated locally or delivered from the gut via portal circulation can only be speculated. Unfortunately, measuring amine levels in human tissue or serum is hampered by rapid amine oxidation, amine volatility and prolonged derivatisation times that preclude analysis in the clinical setting.^{36–37} Nevertheless we have recently shown how mucosa-adherent microbiota in PSC are distinct, with an enrichment of the genus *Escherichia*.¹⁴ The latter are known to produce cysteamine in vitro, as can the potentially oncogenic genus *Enterobacter*.^{20–38–40} Cysteamine may also derive directly from the intestinal epithelium, through the activity of the ectoenzyme vanin-1.⁴¹ Vanin-1 mediates cysteamine release in the gut, and the introduction of cysteamine promotes colonic inflammation and carcinogenesis in vivo.^{28–29–41} These observations have direct relevance to the increased colonic cancer risk in human PSC. Moreover, the aldehyde by-product of




Figure 4 Correlation of serum vascular adhesion protein-1 (sVAP-1) levels with disease severity in primary sclerosing cholangitis (PSC). (A) Circulating soluble vascular adhesion protein-1 (sVAP-1) levels measured via immunofluorescence in PSC (n=134) versus autoimmune hepatitis (AIH, n=90), primary biliary cholangitis (PBC, n=48) and healthy controls (HC, n=54); and (B) versus UC without evidence of PSC (n=50). (C) Serum sVAP-1 levels in patients with PSC are shown according to the severity of liver disease: non-cirrhotic (n=39) versus established cirrhosis (n=95); and (D) in cirrhotic patients with compensated (n=68) versus decompensated liver disease (n=27).

cysteamine deamination is 3-mercaptpropionaldehyde, which is associated with abnormal collagen crosslinking and a potential contributor to fibrogenesis in chronic liver disease.⁴² However, there are no reports of cysteamine being generated within human liver itself.

Although hepatic VAP-1 expression was increased in all immune-mediated liver diseases, this was marked in PSC and mirrored by heightened amine oxidase activity. Notably, hepatic enzyme activity in PSC was similar to that seen in the colon in IBD, and it is plausible that upregulated colonic and hepatic VAP-1 expression may have evolved to cope with an increased burden of amines generated during intestinal inflammation. In such a model, colonic dysbiosis could activate mucosal immune responses leading to colitis, and an increase in amine release from both bacteria and the inflamed epithelium. These substrates when released into the portal vein would enter the liver and activate VAP-1, modulating the expression of adhesion molecules on the hepatic endothelium.⁵ Thus, our data put forward a novel pathway through which colonic inflammation and amine release may lead to liver damage, providing further links between IBD and PSC. In support of this paradigm, mucosa-adherent bacteria in PSC have been shown to be distinct from those found in patients with IBD alone and normal, healthy colon.^{14 43–46}

Taken together with our previously published data, we hypothesise that VAP-1 expression is critical during multiple stages of PSC pathogenesis. In early disease, VAP-1 expression would be increased on hepatic vessels in an effort to catabolise the increased burden of amine substrates delivered via the portal circulation from an inflamed gut. The resultant increase in amine oxidase activity would drive upregulation of endothelial adhesion molecules (including MAdCAM-1), fostering recruitment of $\alpha 4\beta 7^+$ mucosal lymphocytes and leading to a proinflammatory response within the liver. Additionally, the increased expression we observe in fibrous septa and α SMA-positive cells suggest a broader role in advanced liver disease that may not be aetiology-specific, rather characterising a more generalised process contributing to tissue fibrogenesis.¹²

We also found that circulating sVAP-1 concentrations in patients with PSC were elevated versus those with IBD alone and healthy control subjects, and levels were also heightened when compared with patients with PBC and AIH. However, the variation between patients with autoimmune liver disease may reflect a more advanced stage of liver injury in our PSC cohort rather than a true aetiology-specific difference. Indeed, a large proportion of patients with PSC had evidence of cirrhosis at time of serum sampling, with a greater clinical event rate observed during follow-up compared with other immune-

Table 2 Soluble VAP-1 levels according to clinical covariates

| Categorical associations | sVAP-1 level (ng/mL) | | p Value | |
|---|----------------------|---------------|---------------|-------|
| Sex | | | | |
| Male vs female | 529 (432–627) | 567 (457–698) | 0.325 | |
| Disease severity | | | | |
| Non-cirrhotic vs Cirrhotic | 462 (406–547) | 578 (413–736) | 0.006 | |
| Ascending cholangitis within past 3 months* | | | | |
| Presence vs absence | 550 (376–646) | 532 (438–672) | 0.350 | |
| IBD† | | | | |
| Presence vs absence | 532 (431–653) | 542 (438–663) | 0.668 | |
| Active vs inactive | 523 (387–626) | 533 (443–672) | 0.466 | |
| Colectomy vs colon intact | 534 (443–710) | 532 (434–651) | 0.939 | |
| Immunosuppression within past 3 months | | | | |
| Exposure vs absence | 516 (418–621) | 549 (438–663) | 0.630 | |
| UDCA exposure within past 3 months | | | | |
| Treatment vs non-treatment | 534 (451–681) | 457 (413–571) | 0.053 | |
| Antibiotic exposure within past 3 months‡ | | | | |
| Exposure vs absence | 566 (395–621) | 529 (436–672) | 0.600 | |
| ANA | | | | |
| Positive vs negative | 517 (432–696) | 551 (435–631) | 0.857 | |
| ASMA | | | | |
| Positive vs negative | 508 (421–627) | 543 (436–676) | 0.462 | |
| pANCA | | | | |
| Positive vs negative | 517 (436–667) | 552 (436–663) | 0.794 | |
| Child-Turcotte-Pugh score | | | | |
| A vs B vs C | 512 (406–598) | 559 (453–750) | 524 (430–699) | 0.347 |
| Continuous variable correlations | Spearman's ρ | | p Value | |
| Patient age | 0.194 | | 0.027 | |
| Serum AST | –0.002 | | 0.993 | |
| Serum ALT | –0.076 | | 0.691 | |
| Serum ALP (ratio to ULN) | –0.205 | | 0.278 | |
| Serum bilirubin | 0.217 | | 0.250 | |
| Serum albumin | –0.819 | | 0.318 | |
| INR | 0.014 | | 0.941 | |
| Platelet count | –0.585 | | 0.001 | |
| Serum sodium | 0.141 | | 0.113 | |
| Serum creatinine | –0.242 | | 0.197 | |
| MELD score | 0.128 | | 0.149 | |
| IgG | 0.195 | | 0.303 | |

Continuous data presented as medians (IQR in parenthesis).

*A total of 25 patients were noted to have an attack of ascending cholangitis within 3 months of serum sampling.

†A total of 106 patients had a history of IBD (all colitis), of whom 27 had active disease. Another 19 patients had undergone prior colectomy (9 with colonic dysplasia), of which 5 were experiencing pouchitis.

‡Thirty-six patients were exposed to antibiotics within 3 months of serum sampling.

ALP, alkaline phosphatase; ALT, alanine transaminase; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; AST, aspartate transaminase; IgG, immunoglobulin G; INR, international normalised ratio; MELD, model for end-stage liver diseases; pANCA, perinuclear antineutrophil cytoplasmic antibody; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; VAP, vascular adhesion protein.

mediated liver diseases. While we used multivariable statistical analysis to adjust for the presence of liver cirrhosis, it would be incorrect to presume that heightened sVAP-1 levels are a feature unique to PSC, and similar caveats apply to other proposed biomarkers.^{47–48} Notably, sVAP-1 levels were highest in the cirrhotic PSC subgroup and correlated with certain indices of liver disease severity. This observation is important, for elevated sVAP-1 has also been described in patients with non-alcoholic fatty liver disease, predominantly those with a more advanced stage of fibrosis,¹² although prognostic utility in a dedicated clinical outcomes' analysis was not evident in this cohort.

Serum bilirubin and albumin are recognised clinical correlates of liver cirrhosis, and their predictive value in forecasting clinical outcomes in PSC is well described.⁴⁹ These findings were

validated in the present study, in addition to recurrent ascending cholangitis, elevated serum aspartate transaminase (AST) and the presence of liver cirrhosis being identified as further prognostic factors. Moreover, we found that circulating sVAP-1 levels independently predicted transplant-free survival in a prospective series of patients even when restricting analysis to those with cirrhosis, and reciprocally in individuals with a serum bilirubin, serum albumin and/or circulating platelet count within the normal range. This observation suggests that sVAP-1, while not aetiology-specific per se, represents a biologically driven and mechanistically linked surrogate of clinical outcome that can be applied to patients with PSC with an already advanced liver disease stage, in addition to those harbouring normal synthetic function.




Figure 5 Serum vascular adhesion protein-1 (sVAP-1) values predict clinical outcome in primary sclerosing cholangitis (PSC). (A) Event-free survival from time of serum sampling, overall (prospectively evaluated; Birmingham PSC cohort); and (B) stratified according to circulating soluble (s)VAP-1 levels measured via immunofluorescence, with an area under the receiver operator characteristic curve derived cutpoint of 529 ng/mL. Group A: sVAP-1 < 529 ng/mL and Group B: sVAP-1 > 529 ng/mL. (C) A subanalysis of clinical outcome exclusively in patients with established cirrhosis using the same cut-off points. Clinical events: liver transplantation or liver-related death.

Serum sVAP-1 concentrations were determined using two separate techniques applying different internal protein standards. Although the values we obtain show strong intrasample correlation between methods, levels were generally greater when assayed via chemiluminescence. Such variation between techniques is well recognised in clinical practice,^{50–53} and future work exploring the predictive utility of sVAP-1 cut-offs in PSC and other chronic liver diseases must be mindful of the analytical

method applied. As with any newly proposed biomarker, sVAP-1 also requires validation across larger cohorts, with internationally agreed protein standard preparation and reference ranges set at population level. Moreover, to truly interrogate aetiology-specific differences in VAP-1 expression and soluble circulating levels, prospective large-scale collaboration is necessary, with enough statistical power to facilitate propensity score-matched analysis specifically for disease severity.⁵⁴ Equally, it is

Table 3 Covariates associated with future risk of death or liver transplantation in the PSC derivation cohort

| | Univariate analysis | | Multivariable analysis (adjusted for platelet count and serum albumin)* | | Multivariable analysis (adjusted for cirrhosis)* | |
|---|------------------------|---------|---|---------|--|---------|
| | Unadjusted HR (95% CI) | p Value | Adjusted HR (95% CI) | p Value | Adjusted HR (95% CI) | p Value |
| Elevated serum AST (per IU/L increase)† | 1.01 (1.00 to 1.01) | 0.006 | 1.01 (1.00 to 1.02) | 0.003 | 1.02 (1.01 to 1.02) | <0.001 |
| Ascending cholangitis | 2.62 (1.20 to 5.72) | 0.016 | 3.40 (1.46 to 7.90) | 0.004 | 4.23 (1.72 to 10.42) | 0.002 |
| Antibiotic exposure | 1.91 (1.24 to 2.92) | 0.003 | NS | NS | NS | NS |
| Cirrhosis | 6.02 (1.83 to 20.00) | 0.003 | N/A | N/A | 7.69 (2.04 to 27.03) | 0.002 |
| Elevated serum bilirubin (per g/L increase)† | 1.02 (1.012 to 1.03) | <0.001 | NS | NS | N/A | |
| Thrombocytopenia (per 50×10^3 cells decrease)† | 1.22 (1.02 to 1.42) | 0.028 | NS | NS | N/A | |
| Hypoalbuminaemia (per g/L decrease)† | 1.21 (1.12 to 1.30) | <0.001 | 1.18 (1.08 to 1.28) | <0.001 | N/A | |
| sVAP-1 (per 100 ng increase)† | 1.11 (1.11 to 1.22) | 0.002 | (Not included) | | (Not included) | |
| sVAP-1: >529 ng/mL | 3.76 (1.68 to 8.47) | 0.001 | 2.70 (1.03 to 7.14) | 0.043 | 3.85 (1.57 to 9.34) | 0.003 |

*As platelet count and hypoalbuminaemia were used in defining cirrhosis as a covariate, their impact was determined on a singular as well as collective level in a stepwise multivariable Cox regression model.

†Values in parenthesis indicate that the degree of risk (HR in the adjacent columns) increases according to a unit change in the given variable.

AST, aspartate transaminase; NA, not applicable; NS, not significant; PSC, primary sclerosing cholangitis; VAP, vascular adhesion protein.

important for future studies to establish when in the clinical course hepatic VAP-1 expression becomes increased, and the point at which circulating serum levels discriminate high-risk versus low-risk patient groups. Our study carries a further limitation in this regard, given that experiments with liver tissue were restricted to organs retrieved at transplantation, hence already afflicted with end-stage cirrhosis. However, as liver biopsy is not part of routine clinical care in PSC, access to fresh/frozen tissue from early stage/non-cirrhotic patients (although desirable) is rarely feasible for research purposes. Finally, the proposed hypothesis wherein hepatobiliary disease is driven by enteric dysbiosis and dysregulated mucosal immune responses is restricted by the fact that not all patients with PSC manifest clinically overt colitis; and conversely, not all individuals with intestinal inflammation go on to develop liver injury.

In summary, we demonstrate that hepatic VAP-1 enzymatic activity is increased in PSC, capable of supporting the recruitment of mucosal $\alpha\beta 7^+$ lymphocytes to the liver, and determined by potentially gut-derived substrates such as cysteamine. Moreover, serum VAP-1 values correlate with disease severity and are predictive of outcome in PSC, providing utility for risk stratification in clinical practice.⁵⁵ Given its role in mediating $\alpha\beta 7$ /MAdCAM-1 interactions, VAP-1 may also represent a future therapeutic target, which would modulate the trafficking of lymphocytes from the inflamed gut to the liver, and potentially impact fibrogenesis.^{4 5 12} These pleiotropic mechanisms may explain how targeting VAP-1 carries additional benefit compared with $\alpha 4$ inhibition seen in murine models,⁵⁶ and also over other strategies affecting lymphocyte recruitment more broadly, though with deleterious side effects.⁵⁷

Author affiliations

¹National Institute of Health Research Birmingham Liver Biomedical Research Centre Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

²Liver Unit, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK

³Department of Transplantation Medicine, Division of Cancer Medicine, Surgery and Transplantation, Norwegian PSC Research Center, Oslo University Hospital Rikshospitalet, Oslo, Norway

⁴National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway

⁵Department of Internal Medicine IV, University Hospital Jena, Germany

⁶Center for Sepsis Control and Care, University Hospital Jena, Germany

⁷Biotie Therapies Corp., Turku, Finland

⁸MediCity Research Laboratory, University of Turku, Turku, Finland

⁹Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland

¹⁰Department of Cellular Pathology, University Hospitals Birmingham Queen Elizabeth, Birmingham, UK

Collaborators Professor Sirpa Jalkanen; MediCity Research Laboratory, University of Turku, Finland.

Contributors PJT conducted the experiments, performed statistical analysis and wrote all manuscript drafts to submission. JT performed immunohistochemical staining and approved the manuscript to submission. MNV, PE and LWT contributed serum samples from patients and approved the manuscript to submission. TB and EL provided critical insight into experimental design, assisted with cell culture and approved the manuscript to submission. JV and DS performed the VAP-1 immunofluorescence assays and approved the manuscript to submission. SGH reviewed immunohistochemical sections and approved the manuscript to submission. GH contributed patient samples, provided critical insight into study design and approved the manuscript to submission. DHA supervised the study and approved the manuscript to submission. CJW conceived and supervised the study, providing guidance into experimental design, approved the manuscript to submission and is the guarantor of the article.

Funding Wellcome Trust, 10.13039/100004440, 099907/Z/12/Z, National Institute for Health Research, 10.13039/501100000272.

Competing interests PJT is the recipient of a Wellcome Trust Clinical Research Fellowship (Grant ID: 099907/Z/12/Z). PJT, JT, PE, RP, EL, GMH, DHA and CJW

received institutional salary support from the NIHR Birmingham Liver Biomedical Research Centre. This paper presents independent research supported by the Birmingham NIHR Liver Biomedical Research Centre based at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Ethics approval Local Research and Ethics Committee Birmingham.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>

REFERENCES

- Boonstra K, van Erpecum KJ, van Nieuwkerk KJM, *et al*. Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. *Inflamm Bowel Dis* 2012;18:2270–6.
- Hirschfield GM, Karlsen TH, Lindor KD, *et al*. Primary sclerosing cholangitis. *Lancet* 2013;382:1587–99.
- Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. *Clin Res Hepatol Gastroenterol* 2012;36:420–36.
- Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. *J Autoimmun* 2013;46:97–111.
- Trivedi PJ, Adams DH. Gut—liver immunity. *J Hepatol* 2016;64:1187–9.
- Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. *Nat Rev Immunol* 2006;6:682–92.
- Habtezion A, Nguyen LP, Hadeiba H, *et al*. Leukocyte trafficking to the small intestine and colon. *Gastroenterology* 2016;150:340–54.
- Grant AJ, Lalor PF, Hübscher SG, *et al*. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). *Hepatology* 2001;33:1065–72.
- Eksteen B, Grant AJ, Miles A, *et al*. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. *J Exp Med* 2004;200:1511–7.
- Liaskou E, Karikoski M, Reynolds GM, *et al*. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. *Hepatology* 2011;53:661–72.
- Salmi M, Jalkanen S. Ecto-enzymes in leukocyte migration and their therapeutic potential. *Semin Immunopathol* 2014;36:163–76.
- Weston CJ, Shepherd EL, Claridge LC, *et al*. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. *J Clin Invest* 2015;125:501–20.
- Weston CJ, Adams DH. Hepatic consequences of vascular adhesion protein-1 expression. *J Neural Transm (Vienna)* 2011;118:1055–64.
- Quraishi MN, Sergeant M, Kay G, *et al*. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. *Gut* 2017;66:386–8.
- Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 2012;9:671–5.
- Griffiths RL, Sarsby J, Guggenheim EJ, *et al*. Formal lithium fixation improves direct analysis of lipids in tissue by mass spectrometry. *Anal Chem* 2013;85:7146–53.
- Ward ST, Weston CJ, Shepherd EL, *et al*. Evaluation of serum and tissue levels of VAP-1 in colorectal cancer. *BMC Cancer* 2016;16:154.
- Boujedidi H, Bouchet-Delbos L, Cassard-Doulier AM, *et al*. Housekeeping gene variability in the liver of alcoholic patients. *Alcohol Clin Exp Res* 2012;36:258–66.
- Congiu M, Slavin JL, Desmond PV. Expression of common housekeeping genes is affected by disease in human hepatitis C virus-infected liver. *Liver Int* 2011;31:386–90.
- Shen SH, Wertz DL, Klinman JP. Implication for functions of the ectopic adipocyte copper amine oxidase (AOC3) from purified enzyme and cell-based kinetic studies. *PLoS ONE* 2012;7:e29270.
- Shetty S, Weston CJ, Adams DH, *et al*. A flow adhesion assay to study leukocyte recruitment to human hepatic sinusoidal endothelium under conditions of shear stress. *J Vis Exp* 2014;85:51330.
- Aalto K, Havulinna AS, Jalkanen S, *et al*. Soluble vascular adhesion protein-1 predicts incident major adverse cardiovascular events and improves reclassification in a Finnish prospective cohort study. *Circ Cardiovasc Genet* 2014;7:529–35.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. *J Hepatol* 2009;51:237–67.
- Jeitner TM, Lawrence DA. Mechanisms for the cytotoxicity of cysteamine. *Toxicol Sci* 2001;63:57–64.
- Sikiric P, Seiwert S, Grabarevic Z, *et al*. Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. *J Physiol Paris* 2001;95:261–70.

- 26 Pitari G, Malergue F, Martin F, *et al.* Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. *FEBS Lett* 2000;483:149–54.
- 27 Klicek R, Kolenc D, Suran J, *et al.* Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. *J Physiol Pharmacol* 2013;64:597–612.
- 28 Martin F, Penet MF, Malergue F, *et al.* Vanin-1^{-/-} mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. *J Clin Invest* 2004;113:591–7.
- 29 Berruyer C, Pouyet L, Millet V, *et al.* Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. *J Exp Med* 2006;203:2817–27.
- 30 Gensollen T, Bourges C, Rihet P, *et al.* Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. *Inflamm Bowel Dis* 2013;19:2315–25.
- 31 Lalor PF, Sun PJ, Weston CJ, *et al.* Activation of vascular adhesion protein-1 on liver endothelium results in an NF-kappaB-dependent increase in lymphocyte adhesion. *Hepatology* 2007;45:465–74.
- 32 Aspinall AI, Curbishley SM, Lalor PF, *et al.* CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium. *Hepatology* 2010;51:2030–9.
- 33 Shetty S, Bruns T, Weston CJ, *et al.* Recruitment mechanisms of primary and malignant B cells to the human liver. *Hepatology* 2012;56:1521–31.
- 34 Zimmermann HW, Bruns T, Weston CJ, *et al.* Bidirectional transendothelial migration of monocytes across hepatic sinusoidal endothelium shapes monocyte differentiation and regulates the balance between immunity and tolerance in liver. *Hepatology* 2016;63:233–46.
- 35 Stolen CM, Yegutkin GG, Kurkijärvi R, *et al.* Origins of serum semicarbazide-sensitive amine oxidase. *Circ Res* 2004;95:50–7.
- 36 Stachowicz M, Lehmann B, Tibi A, *et al.* Determination of total cysteamine in human serum by a high-performance liquid chromatography with fluorescence detection. *J Pharm Biomed Anal* 1998;17:767–73.
- 37 Xiao S, Yu PH. A fluorometric high-performance liquid chromatography procedure for simultaneous determination of methylamine and aminoacetone in blood and tissues. *Anal Biochem* 2009;384:20–6.
- 38 Soriano BD, Tam LT, Lu HS, *et al.* A fluorescent-based HPLC assay for quantification of cysteine and cysteamine adducts in Escherichia coli-derived proteins. *J Chromatogr B* 2012;880:27–33.
- 39 Ghenghesh KS, Drucker DB. Gas liquid chromatography of amines produced by the Enterobacteriaceae. *Braz J Med Biol Res Rev* 1989;22:653–65.
- 40 Yurdakul D, Yazgan-Karataş A, Şahin F. Enterobacter strains might promote colon cancer. *Curr Microbiol* 2015;71:403–11.
- 41 Pouyet L, Roisin-Bouffay C, Clément A, *et al.* Epithelial vanin-1 controls inflammation-driven carcinogenesis in the colitis-associated colon cancer model. *Inflamm Bowel Dis* 2010;16:96–104.
- 42 Povero D, Eguchi A, Niesman IR, *et al.* Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. *Sci Signal* 2013;6:ra88.
- 43 Sabino J, Vieira-Silva S, Machiels K, *et al.* Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. *Gut* 2016;65:1681–9.
- 44 Kummen M, Holm K, Anmarkrud JA, *et al.* The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. *Gut* 2017;66:611–19.
- 45 Torres J, Bao X, Goel A, *et al.* The features of mucosa-associated microbiota in primary sclerosing cholangitis. *Aliment Pharmacol Ther* 2016;43:790–801.
- 46 Kevans D, Tyler AD, Holm K, *et al.* Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis. *J Crohns Colitis* 2016;10:330–7.
- 47 Vesterhus M, Hov JR, Holm A, *et al.* Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. *Hepatology* 2015;62:188–97.
- 48 Corpechot C, Gaouar F, El Naggar A, *et al.* Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. *Gastroenterology* 2014;146:970–9.
- 49 Tischendorf JJW, Hecker H, Krüger M, *et al.* Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. *Am J Gastroenterol* 2007;102:107–14.
- 50 Infantino M, Meacci F, Bentow C, *et al.* Clinical comparison of QUANTA Flash dsDNA chemiluminescent immunoassay with four current assays for the detection of anti-dsDNA autoantibodies. *J Immunol Res* 2015;2015:902821.
- 51 Dipalo M, Guido L, Micca G, *et al.* Multicenter comparison of automated procalcitonin immunoassays. *Pract Lab Med* 2015;2:2–8.
- 52 Stinton LM, Bentow C, Mahler M, *et al.* PR3-ANCA: a promising biomarker in Primary Sclerosing Cholangitis (PSC). *PLoS ONE* 2014;9:e112877.
- 53 Pecori Giralaldi F, Saccani A, Cavagnini F, Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of Endocrinology. Assessment of ACTH assay variability: a multicenter study. *Eur J Endocrinol* 2011;164:505–12.
- 54 Shim JH, Yoon DL, Han S, *et al.* Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. *Ann Surg Oncol* 2012;19:3687–96.
- 55 Trivedi PJ, Corpechot C, Pares A, *et al.* Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists. *Hepatology* 2016;63:644–59.
- 56 Lee WY, Salmi M, Kelly MM, *et al.* Therapeutic advantage of anti-VAP-1 over anti- $\alpha 4$ integrin antibody in concanavalin a-induced hepatitis. *Hepatology* 2013;58:1413–23.
- 57 Franceschet I, Cazzagon N, Del Ross T, *et al.* Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. *Eur J Gastroenterol Hepatol* 2016;28:508–13.